Extracting functional groups of ALLINI to design derivatives of FDA‐approved drugs: Inhibition of HIV‐1 integrase - Publication - Bridge of Knowledge

Your account

login

Search

Extracting functional groups of ALLINI to design derivatives of FDA‐approved drugs: Inhibition of HIV‐1 integrase

Abstract

HIV‐1 integrase (IN) is crucial for integration of viral DNA into the host genome and a promising target in development of antiretroviral inhibitors. In this work, six new compounds were designed by linking the structures of two different class of HIV‐1 IN inhibitors (active site binders and allosteric IN inhibitors (ALLINIs)). Among newly designed compounds, INRAT10b was found most potent HIV‐1 IN inhibitor considering different docking results. To further validate protein–ligand interactions obtained from dockings, molecular dynamics simulations were performed for inhibitor raltegravir and INRAT10b placed either at active site or allosteric site of HIV‐1 IN (monomer or dimer). Results suggest that both raltegravir and INRAT10b were interacting with residue Gln62, Gly140, Ile141, and Ser147. However, INRAT10b interacts better with high H‐bond occupancy, which can explain the strong binding affinity of INRAT10b than raltegravir with the HIV‐1 IN protein. Subdomains rearrangements in HIV‐1 IN suggest that the C‐terminal and catalytic core domains develop their closeness in the presence of ligand. More significantly, the newly designed derivatives represent novel compounds targeting catalytic site and C‐terminal (protein–protein interaction) domains simultaneously. And we also propose INRAT10b as a promising lead compound for the development of potent HIV‐1 IN inhibitors.

Citations

  • 0

    CrossRef

  • 0

    Web of Science

  • 0

    Scopus

Authors (3)

Cite as

Full text

full text is not available in portal

Keywords

Details

Category:
Articles
Type:
artykuł w czasopiśmie wyróżnionym w JCR
Published in:
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY no. 65, pages 594 - 607,
ISSN: 0885-4513
Language:
English
Publication year:
2018
Bibliographic description:
Kalathiya U., Padariya M., Bagiński M.: Extracting functional groups of ALLINI to design derivatives of FDA‐approved drugs: Inhibition of HIV‐1 integrase// BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY. -Vol. 65, iss. 4 (2018), s.594-607
DOI:
Digital Object Identifier (open in new tab) 10.1002/bab.1646
Verified by:
Gdańsk University of Technology

seen 133 times

Recommended for you

Molecular basis and potential activity of HIV-1 reverse transcriptase toward trimethylamine-based compounds

2017

Molecular modeling and evaluation of novel dibenzopyrrole derivatives as telomerase inhibitors and potential drug for cancer therapy

2014

Divulging the anti-acetylcholinesterase activity of Colletotrichum lentis strain KU1 extract as sustainable AChE active site inhibitors

2022

Structure-based design and evaluation of novel N-phenyl-1H-indol-2-amine derivatives for fat mass and obesity-associated (FTO) protein inhibition

2016
Meta Tags